Document Detail


Clinical significance of anticardiolipin and anti-beta2-glycoprotein I antibodies.
MedLine Citation:
PMID:  15345914     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Anticardiolipin (aCl) and anti-beta2-glycoprotein I (anti-beta2-gpI) antibodies are autoantibodies associated with the antiphospholipid syndrome (APS), which is characterized by both arterial and venous thrombosis and miscarriages. The scope of this study was to explore the clinical characteristics of patients with aCl and anti-beta2-gpI antibodies. METHODS: ACl were tested in 3,600 consecutive sera in our laboratory between January 1999 and June 2001. The clinical diagnosis and prevalence of thrombosis and pregnancy morbidity were retrospectively reviewed in aCl-positive patients. Furthermore, the frequency of anti-beta2-gpI antibodies, lupus anticoagulant (LA), prolonged activated partial thromboplastin time (aPTT), and thrombocytopenia were investigated in aCl-positive patients. RESULTS: 147 aCl-positive patients, 110 women and 37 men with a mean age of 41 years (range 7.8-82.5), were identified. 42 (28.6%) aCl-positive patients fulfilled the criteria for APS which was secondary to a connective tissue disorder in 8 patients. The frequency of anti-beta2-gpI antibodies and LA, prolonged aPTT, and thrombocytopenia in aCl-positive patients was 23.8, 27.2, 25.7 and 9.2%, respectively. The presence of both aCl and anti-beta2-gpI antibodies was strongly associated with clinical symptoms of APS (p = 0.007) compared to p = 0.008 for LA. CONCLUSION: Our data suggest that assessment of anti-beta2-gpI antibodies in addition to aCl is a valuable diagnostic tool in the workup of patients with APS.
Authors:
Gerlinde Obermoser; Waltraud Bitterlich; Friedebert Kunz; Norbert T Sepp
Related Documents :
17558704 - Hematological presentation in systemic lupus erythematosus and its relationship with di...
17283584 - Analysis of risk factors for the development of thrombotic complications in antiphospho...
20026524 - Identification of autoantigens specific for systemic lupus erythematosus with central n...
18506734 - Toxicity of radiotherapy in patients with collagen vascular disease.
8423914 - Dominantly inherited, early-onset parkinsonism: neuropathology of a new form.
3565284 - Transient cardiac constriction: an unrecognized pattern of evolution in effusive acute ...
Publication Detail:
Type:  Journal Article     Date:  2004-09-02
Journal Detail:
Title:  International archives of allergy and immunology     Volume:  135     ISSN:  1018-2438     ISO Abbreviation:  Int. Arch. Allergy Immunol.     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-10-06     Completed Date:  2004-11-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9211652     Medline TA:  Int Arch Allergy Immunol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  148-53     Citation Subset:  IM    
Affiliation:
Department of Dermatology, University Hospital of Innsbruck, Innsbruck, Austria. Gerlinde.Obermoser@uibk.ac.at
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies / blood
Antibodies, Anticardiolipin / blood*
Antiphospholipid Syndrome / blood,  complications,  diagnosis*
Child
Connective Tissue Diseases / complications,  epidemiology
Female
Fetal Death
Glycoproteins / immunology*
Humans
Lupus Coagulation Inhibitor / blood
Male
Middle Aged
Partial Thromboplastin Time
Pregnancy
Prevalence
Sensitivity and Specificity
Thrombocytopenia / epidemiology
Thrombosis / epidemiology
beta 2-Glycoprotein I
Chemical
Reg. No./Substance:
0/Antibodies; 0/Antibodies, Anticardiolipin; 0/Glycoproteins; 0/Lupus Coagulation Inhibitor; 0/beta 2-Glycoprotein I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine ...
Next Document:  Canine mast cell activation via human IgG1 and IgG4.